<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Breast sarcoma: Epidemiology, risk factors, clinical presentation, diagnosis, and staging
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Breast sarcoma: Epidemiology, risk factors, clinical presentation, diagnosis, and staging
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Breast sarcoma: Epidemiology, risk factors, clinical presentation, diagnosis, and staging
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Rashmi Chugh, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Michael S Sabel, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Mary Feng, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Robert Maki, MD, PhD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Daniel F Hayes, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Anees B Chagpar, MD, MSc, MA, MPH, MBA, FACS, FRCS(C)
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Elizabeth H Baldini, MD, MPH, FASTRO
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Melinda Yushak, MD, MPH
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Oct 20, 2021.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Breast sarcomas are rare, histologically heterogeneous nonepithelial malignancies that arise from the connective tissue within the breast [
         <a href="#rid1">
          1
         </a>
         ]. They can develop de novo (primary), after radiation therapy (RT), or in the setting of lymphedema of the arm or breast after treatment of another malignancy (therapy related, secondary) [
         <a href="#rid2">
          2-6
         </a>
         ]. Although the clinical features of breast sarcoma mimic those of breast carcinoma in some ways, therapy and prognosis differ dramatically.
        </p>
        <p>
         This topic review will cover the epidemiology, risk factors, clinical features, diagnosis, and staging of breast sarcoma. Treatment and prognosis are discussed elsewhere, as are other nonepithelial breast tumors, including breast lymphomas, phyllodes tumors (including cystosarcoma phyllodes), and desmoid tumors of the breast. (See
         <a class="medical medical_review" href="/z/d/html/83132.html" rel="external">
          "Breast sarcoma: Treatment"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/793.html" rel="external">
          "Phyllodes tumors of the breast"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7746.html" rel="external">
          "Desmoid tumors: Epidemiology, molecular pathogenesis, clinical presentation, diagnosis, and local therapy", section on 'Breast desmoids'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4711.html" rel="external">
          "Overview of the pathobiology of the non-Hodgkin lymphomas", section on 'Introduction'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3320653">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Breast sarcomas are rare; they account for less than 1 percent of all breast malignancies [
         <a href="#rid7">
          7
         </a>
         ] and less than 5 percent of all soft tissue sarcomas [
         <a href="#rid8">
          8
         </a>
         ]. In data compiled from the Surveillance, Epidemiology, and End Results (SEER) program of the National Cancer Institute (NCI), the annual incidence of breast sarcomas was 4.6 cases per million women [
         <a href="#rid9">
          9
         </a>
         ].
        </p>
        <p>
         The specific incidence of secondary, therapy-related breast sarcomas is difficult to discern. Secondary or treatment-related breast sarcomas most frequently arise following breast cancer treatment with radiation therapy (RT). However, the absolute magnitude of the risk of a secondary breast sarcoma in women who undergo RT for breast cancer appears to be small  (
         <a class="graphic graphic_table graphicRef61730" href="/z/d/graphic/61730.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p>
         Angiosarcoma is the specific sarcoma type that is associated most strongly with treatment for a previous breast cancer. In a population-based study in Los Angeles County, the adjusted relative risk of developing an angiosarcoma for women with a prior diagnosis of breast cancer compared with women without breast cancer was 59 (95% CI 22-153) [
         <a href="#rid10">
          10
         </a>
         ]. Furthermore, women who receive RT as a component of breast cancer treatment have a 9- to 16-fold increase in the relative risk of developing an angiosarcoma relative to those treated with other modalities [
         <a href="#rid6">
          6,11
         </a>
         ]. However, despite these high relative risks, the absolute magnitude of risk for a treatment-related angiosarcoma after RT remains small  (
         <a class="graphic graphic_table graphicRef61730" href="/z/d/graphic/61730.html" rel="external">
          table 1
         </a>
         ). The association between ionizing RT and breast sarcomas is discussed in more detail below. (See
         <a class="local">
          'Ionizing radiation'
         </a>
         below.)
        </p>
        <p>
         The average age at presentation is 45 to 50 years (range 17 to 89) [
         <a href="#rid7">
          7,9,12-15
         </a>
         ]. The vast majority of primary breast sarcomas arise in women, although cases are described in men [
         <a href="#rid16">
          16
         </a>
         ]. Men accounted for 1.5 percent of cases of breast sarcoma in a compilation of published reports [
         <a href="#rid17">
          17
         </a>
         ].
        </p>
        <p>
         Primary breast angiosarcomas tend to occur in somewhat younger women; the average age at diagnosis is under 40 years in most series [
         <a href="#rid10">
          10,18-21
         </a>
         ]. In contrast, the average age of occurrence for treatment-related angiosarcomas is older (median 64, range 44 to 84 years) [
         <a href="#rid18">
          18,20,22
         </a>
         ]. This may be related, at least in part, to the increased prevalence of epithelial breast cancer in older patients. Information about the latency period between RT and the development of radiation-associated breast sarcomas is found below. (See
         <a class="local">
          'Ionizing radiation'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          RISK FACTORS
         </span>
         <span class="headingEndMark">
          —
         </span>
         A causative factor for the formation of primary soft tissue sarcomas cannot be identified in many patients with primary breast sarcomas [
         <a href="#rid23">
          23
         </a>
         ]. In contrast, secondary breast sarcomas are associated with prior radiation therapy (RT) and conditions causing chronic lymphedema [
         <a href="#rid2">
          2-6,11,24
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/14261.html" rel="external">
          "Radiation-associated sarcomas"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/104714.html" rel="external">
          "Breast cancer-associated lymphedema"
         </a>
         .)
        </p>
        <p>
         There is no proven association between breast implants and breast sarcomas in humans. (See
         <a class="medical medical_review" href="/z/d/html/15779.html" rel="external">
          "Complications of reconstructive and aesthetic breast surgery", section on 'Anaplastic large cell lymphoma'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/96116.html" rel="external">
          "Implant-based breast reconstruction and augmentation", section on 'Concerns over breast implants'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H30564621">
         <span class="h2">
          Ionizing radiation
         </span>
        </p>
        <p class="headingAnchor" id="H1890919159">
         <span class="h3">
          Classification of radiation-associated sarcoma
         </span>
         <span class="headingEndMark">
          —
         </span>
         Ionizing radiation is a well-documented risk factor for secondary breast sarcoma. The classification of a tumor as a radiation-associated sarcoma generally requires that the following criteria be met [
         <a href="#rid25">
          25
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Evidence of an initial malignant tumor of a different histology than the putative radiation-associated sarcoma
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Development of the sarcoma in an irradiated field
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A prolonged latency period (typically &gt;4 years) between the two malignancies
        </p>
        <p>
        </p>
        <p>
         Secondary or treatment-related breast sarcomas most frequently arise following breast cancer treatment with RT, either as part of breast-conserving therapy or after mastectomy [
         <a href="#rid25">
          25-30
         </a>
         ]. However, secondary breast sarcomas can also follow RT for other malignancies (eg, lymphoma) when the breast and/or chest wall are included in the irradiated field [
         <a href="#rid4">
          4
         </a>
         ].
        </p>
        <p>
         As with sarcomas at any location, the risk of a radiation-associated breast sarcoma generally increases with higher doses of RT [
         <a href="#rid27">
          27,31
         </a>
         ]. In addition, the risk of secondary sarcoma is higher when patients are irradiated as children than as adults, particularly in those receiving both RT and chemotherapy [
         <a href="#rid32">
          32
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4764.html" rel="external">
          "Second malignancies after treatment of classic Hodgkin lymphoma", section on 'Bone and soft tissue cancer'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7737.html" rel="external">
          "Pathogenetic factors in soft tissue and bone sarcomas", section on 'Radiation therapy and chemotherapy'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H9239667">
         <span class="h3">
          Radiation exposure in breast cancer survivors
         </span>
         <span class="headingEndMark">
          —
         </span>
         The early detection of breast cancer through mammographic screening, and improvements in adjuvant therapy have increased the number of breast cancer survivors who are potentially cured of their disease and live long enough to develop late effects of treatment, which include secondary malignancies such as therapy-related sarcomas. (See
         <a class="medical medical_review" href="/z/d/html/754.html" rel="external">
          "Overview of long-term complications of therapy in breast cancer survivors and patterns of relapse", section on 'Risks associated with radiation therapy'
         </a>
         .)
        </p>
        <p>
         Although women who undergo RT for breast cancer have an increased risk of in-field sarcomas that persists for 20 to 30 years, the absolute magnitude of the risk appears to be small  (
         <a class="graphic graphic_table graphicRef61730" href="/z/d/graphic/61730.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid2">
          2,6,11,33-37
         </a>
         ]. The average latency period for secondary sarcomas after RT for breast carcinoma is approximately 10 to 11 years, but it may be as long as 44 years and as short as six months [
         <a href="#rid3">
          3-5,33,38-41
         </a>
         ]. The latency period is shorter for angiosarcomas, which tend to occur four to eight years posttreatment [
         <a href="#rid5">
          5,10,22,41-45
         </a>
         ].
        </p>
        <p>
         It is not known whether newer radiation techniques, such as intensity-modulated RT (IMRT; which decreases the volume of breast tissue exposed to high RT doses but increases the volume exposed to low doses of irradiation [
         <a href="#rid46">
          46
         </a>
         ]) or hypofractionated regimens, may influence the risk of a radiation-associated sarcoma. (See
         <a class="medical medical_review" href="/z/d/html/789.html" rel="external">
          "Radiation therapy techniques for newly diagnosed, non-metastatic breast cancer"
         </a>
         .)
        </p>
        <p>
         The potential benefit of RT in the treatment of breast carcinoma usually outweighs the small risk of a treatment-related sarcoma [
         <a href="#rid6">
          6
         </a>
         ]. Nevertheless, the risk is real, and in some cases, it may impact a patient's choice of therapy. As an example, women who have inherited mutations in the ataxia-telangiectasia mutated (
         <em>
          ATM
         </em>
         ) gene, which are associated with an increased risk of radiation-associated sarcoma, may choose to avoid breast-conserving therapy, opting instead for mastectomy. (See
         <a class="local">
          'Inherited conditions'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/739.html" rel="external">
          "Adjuvant radiation therapy for women with newly diagnosed, non-metastatic breast cancer"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6233.html" rel="external">
          "Ataxia-telangiectasia", section on 'Malignancy'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H751986">
         <span class="h2">
          Lymphedema
         </span>
         <span class="headingEndMark">
          —
         </span>
         Chronic arm or breast edema increases the risk of sarcoma after breast cancer treatment, particularly angiosarcoma. Angiosarcomas can also develop in extremities with chronic lymphedema of any etiology [
         <a href="#rid47">
          47
         </a>
         ].
        </p>
        <p>
         Lymphangiosarcomas of the upper extremity, breast, and axilla arising in women with chronic lymphedema after breast cancer therapy were initially described by Stewart and Treves, and this syndrome is now designated Stewart-Treves syndrome [
         <a href="#rid24">
          24
         </a>
         ]. Such women typically present with longstanding extensive arm edema after mastectomy and axillary lymph node dissection, although it may occur after RT alone (due to axillary lymph node sclerosis) and is most common in patients who undergo both axillary RT and surgery. (See
         <a class="medical medical_review" href="/z/d/html/755.html" rel="external">
          "Clinical features and diagnosis of peripheral lymphedema"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4672806">
         <span class="h2">
          Inherited conditions
         </span>
         <span class="headingEndMark">
          —
         </span>
         As with other soft tissue sarcomas, there are rarely some predisposing genetic conditions for breast sarcoma, including Li-Fraumeni syndrome, familial adenomatous polyposis (FAP) and its variants, or neurofibromatosis type 1 (NF1) [
         <a href="#rid48">
          48
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7737.html" rel="external">
          "Pathogenetic factors in soft tissue and bone sarcomas", section on 'Genetic predisposition'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/14255.html" rel="external">
          "Li-Fraumeni syndrome"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2593.html" rel="external">
          "Clinical manifestations and diagnosis of familial adenomatous polyposis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2939.html" rel="external">
          "Neurofibromatosis type 1 (NF1): Pathogenesis, clinical features, and diagnosis", section on 'Soft tissue sarcomas'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4672598">
         <span class="h2">
          Environmental factors
         </span>
         <span class="headingEndMark">
          —
         </span>
         Besides ionizing irradiation, environmental exposures linked to sarcomas in general include arsenic compounds, vinyl chloride, herbicides, immunosuppressive agents, and in the case of Kaposi sarcoma, HIV and human herpes virus 8 (HHV-8). (See
         <a class="medical medical_review" href="/z/d/html/8033.html" rel="external">
          "AIDS-related Kaposi sarcoma: Clinical manifestations and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7737.html" rel="external">
          "Pathogenetic factors in soft tissue and bone sarcomas", section on 'Radiation therapy and chemotherapy'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7737.html" rel="external">
          "Pathogenetic factors in soft tissue and bone sarcomas", section on 'Industrial chemicals'
         </a>
         .)
        </p>
        <p>
         Although exposure to chemotherapy, particularly alkylating agents, has been implicated in radiation-associated sarcomas, a systematic review of nine studies found no evidence that chemotherapy is a contributing risk factor for radiation-associated breast sarcoma, at least in adults [
         <a href="#rid25">
          25
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H529562">
         <span class="h1">
          HISTOLOGIC CLASSIFICATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         As with other non-breast soft tissue sarcomas, primary breast sarcomas are histologically heterogeneous. (See
         <a class="medical medical_review" href="/z/d/html/14259.html" rel="external">
          "Clinical presentation, histopathology, diagnostic evaluation, and staging of soft tissue sarcoma", section on 'Histopathology'
         </a>
         .)
        </p>
        <p>
         Histologic review by an experienced soft tissue pathologist is critical in making the diagnosis and determining histologic type. Evaluation of type distribution in the breast is limited not only by the rarity of the disease, but also by heterogeneity in the way these tumors have been classified [
         <a href="#rid7">
          7,9
         </a>
         ]. Disparate classification schemes have often been used, obscuring distinctions in clinical course and prognosis among the different histologic entities, as illustrated by the following observations:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Some authors exclude malignant phyllodes tumor (cystosarcoma phyllodes) from breast sarcoma studies because these tumors have a benign epithelial component in addition to a malignant mesenchymal component. Others classify malignant phyllodes tumors as a type of breast sarcoma because of the similar survival and clinical course [
         <a href="#rid7">
          7,9,12,49
         </a>
         ]. Phyllodes tumors of the breast are considered separately. (See
         <a class="medical medical_review" href="/z/d/html/793.html" rel="external">
          "Phyllodes tumors of the breast"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Some series include carcinosarcomas of the breast (metaplastic carcinoma), which represent various combinations of poorly differentiated ductal adenocarcinoma, and mesenchymal (sarcomatous) and other epithelial cell (eg, squamous) components. However, most clinicians classify and treat these tumors as an aggressive variant of ductal adenocarcinoma rather than a sarcoma. (See
         <a class="medical medical_review" href="/z/d/html/783.html" rel="external">
          "Pathology of breast cancer", section on 'Metaplastic carcinoma'
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         In general, in series that are inclusive of all typical sarcoma types, angiosarcomas and undifferentiated pleomorphic sarcomas (formerly included in a broad category that was termed malignant fibrous histiocytoma) comprise the major types. Subsets of undifferentiated/unclassified soft tissue sarcomas include the pleomorphic, round cell, and spindle cell variants. (See
         <a class="medical medical_review" href="/z/d/html/14259.html" rel="external">
          "Clinical presentation, histopathology, diagnostic evaluation, and staging of soft tissue sarcoma", section on 'Histopathology'
         </a>
         .)
        </p>
        <p>
         In one large series of 991 patients with nonangiosarcoma breast sarcoma in the National Cancer Database, the histologic subtype distribution was as follows [
         <a href="#rid50">
          50
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Sarcoma, not otherwise specified – 26 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Spindle cell sarcoma – 14 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Leiomyosarcoma – 12 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Giant cell sarcoma – 10 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Stromal sarcoma – 6 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Malignant fibrous histiocytoma – 6 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Fibromyxosarcoma – 4 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Dermatofibrosarcoma protuberans – 3 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Fibrosarcoma – 3 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Undifferentiated – 3 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Liposarcoma – 3 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Pleomorphic liposarcoma – 2 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Others – 8 percent
        </p>
        <p>
        </p>
        <p>
         This distribution of histologies included a large number of "not otherwise specified," which further emphasizes the importance of pathologic review by a sarcoma pathologist. Many such histologies have been reclassified or are able to be refined with the use of additional immunohistochemical staining or molecular diagnostics. Other series also indicate the diversity of histologies that can present in the breast and include such additional histologies including solitary fibrous tumor and osteosarcoma [
         <a href="#rid13">
          13
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/88706.html" rel="external">
          "Solitary fibrous tumor"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7722.html" rel="external">
          "Osteosarcoma: Epidemiology, pathology, clinical presentation, and diagnosis"
         </a>
         .)
        </p>
        <p>
         In series that include angiosarcomas and particularly those with a high percentage of therapy-related breast sarcomas, angiosarcomas are the most common tumor type [
         <a href="#rid14">
          14,15,41,51
         </a>
         ]. Angiosarcomas comprised almost one-half of all histologic subtypes in series of secondary breast sarcomas [
         <a href="#rid6">
          6,11,41
         </a>
         ].
        </p>
        <p>
         Angiosarcomas are sometimes referred to as either lymphangiosarcomas or hemangiosarcomas (derived from lymphatic and capillary endothelium, respectively). As this distinction can be quite difficult histologically and is not always clearly defined, both subtypes will be referred to collectively as angiosarcomas for the purpose of this review.
        </p>
        <p>
         Angiosarcomas have a poor prognosis relative to other subtypes; they behave in a locally aggressive fashion and often metastasize to distant sites. Although there is no apparent prognostic relevance for other histologic subtypes, histology-specific treatment is becoming more commonplace. (See
         <a class="medical medical_review" href="/z/d/html/83132.html" rel="external">
          "Breast sarcoma: Treatment", section on 'Outcomes'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H10858421">
         <span class="h2">
          Grading
         </span>
         <span class="headingEndMark">
          —
         </span>
         The features that are used to assign a histologic grade of differentiation are the extent of tissue differentiation, the mitotic count, the presence or absence of necrosis, cellularity, and pleomorphism. Histologic grade is an important prognostic factor for soft tissue sarcomas, including those arising in the breast. One exception is that the importance of grade in the prognosis of angiosarcoma is disputed. Although some series indicate a better prognosis for low-grade tumors [
         <a href="#rid52">
          52-55
         </a>
         ], others do not [
         <a href="#rid21">
          21,56
         </a>
         ], and grading is generally not recommended for angiosarcoma [
         <a href="#rid57">
          57,58
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/14259.html" rel="external">
          "Clinical presentation, histopathology, diagnostic evaluation, and staging of soft tissue sarcoma", section on 'Histologic grade'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/83132.html" rel="external">
          "Breast sarcoma: Treatment", section on 'Outcomes'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h1">
          CLINICAL FEATURES AND DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Breast sarcomas most often present as a unilateral, well-defined, large, painless, firm mass within the breast; they are rarely bilateral. They are usually larger in size than are epithelial breast cancers (median size 5 to 6 cm) and are often characterized by a rapid increase in size [
         <a href="#rid5">
          5,9,59
         </a>
         ].
        </p>
        <p>
         Breast skin and the nipple-areola complex are only rarely involved by breast sarcomas [
         <a href="#rid60">
          60-62
         </a>
         ]. However, angiosarcomas are the exception; they may be associated with skin thickening, erythema, or skin discoloration with an overlying bluish tint [
         <a href="#rid9">
          9,42
         </a>
         ]. These findings are sometimes mistaken for cellulitis or a hematoma. (See
         <a class="local">
          'Differential diagnosis'
         </a>
         below.)
        </p>
        <p>
         Therapy-related angiosarcomas have a distinct appearance, presenting as single or multiple ecchymotic macular or purplish papular cutaneous lesions in the breast  (
         <a class="graphic graphic_picture graphicRef86979" href="/z/d/graphic/86979.html" rel="external">
          picture 1
         </a>
         ) or an edematous upper extremity. Clinically, breast sarcomas often exhibit more rapid growth than do epithelial breast cancers. As with other breast sarcomas, tumor size can be quite large, ranging from 1.5 to 30 cm (median 5 to 6 cm) [
         <a href="#rid7">
          7,9,13,53,63
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H4675516">
         <span class="h2">
          Diagnosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         A breast sarcoma may be suspected based on physical examination and/or imaging. However, the findings may be similar to those of a primary breast cancer or a benign entity, and accurate tissue diagnosis requires a biopsy.
        </p>
        <p class="headingAnchor" id="H11242979">
         <span class="h3">
          Imaging
         </span>
         <span class="headingEndMark">
          —
         </span>
         Findings on mammography are nonspecific; calcifications and spiculation are usually absent. In a series of 24 women with primary breast sarcomas, the predominant mammographic finding was a noncalcified oval mass with indistinct margins [
         <a href="#rid64">
          64
         </a>
         ]. Some tumors may be mistaken for benign lesions, such as fibroadenomas [
         <a href="#rid23">
          23,65
         </a>
         ]. The mammogram may be negative even in the setting of a large palpable mass or skin changes [
         <a href="#rid66">
          66-69
         </a>
         ]. Therapy-related sarcomas may be more difficult to detect mammographically because of postsurgical or postradiation changes, but nodular masses may be present  (
         <a class="graphic graphic_diagnosticimage graphicRef86977" href="/z/d/graphic/86977.html" rel="external">
          image 1
         </a>
         ).
        </p>
        <p>
         Once the tumor is diagnosed as a breast sarcoma, breast magnetic resonance imaging (MRI) is often helpful to more closely examine disease extent preoperatively, particularly in locally advanced tumors near the chest wall. Malignant tumors typically display rapid contrast enhancement with washout characteristics [
         <a href="#rid64">
          64,67,70-73
         </a>
         ]. The borders are often indistinct, and enhancement is inhomogeneous [
         <a href="#rid64">
          64
         </a>
         ]. The MRI appearance of an angiosarcoma is characteristic, with low signal intensity on T1-weighted images but high signal intensity on heavily T2-weighted images, suggesting the presence of vascular channels containing slow-flowing blood [
         <a href="#rid74">
          74,75
         </a>
         ].
        </p>
        <p>
         MRI can also provide information on the extent of disease within the skin  (
         <a class="graphic graphic_diagnosticimage graphicRef86977" href="/z/d/graphic/86977.html" rel="external">
          image 1
         </a>
         ), as well as the presence or absence of involvement of the deep fascia and pectoralis muscle, which is important in planning the surgical approach [
         <a href="#rid67">
          67,70-72,74
         </a>
         ].
        </p>
        <p>
         However, as with other imaging modalities, MRI can underestimate the extent of disease. In particular, cutaneous angiosarcomas are not well visualized with any imaging modality, including MRI. If clinical suspicion for disease is high based on physical examination despite normal imaging findings, a diagnostic tissue biopsy should be pursued.
        </p>
        <p class="headingAnchor" id="H3321882">
         <span class="h3">
          Biopsy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Incisional, excisional, and core needle biopsy all can provide a definitive diagnosis. Core biopsy is generally considered the procedure of choice. If sarcoma is suspected, fine needle aspiration (FNA) is strongly discouraged as it has a low diagnostic accuracy for sarcoma and a false negative result may lead to a delay in diagnosis. In addition, determination of histologic type and grade is seldom possible with FNA. (See
         <a class="medical medical_review" href="/z/d/html/14259.html" rel="external">
          "Clinical presentation, histopathology, diagnostic evaluation, and staging of soft tissue sarcoma", section on 'Biopsy'
         </a>
         .)
        </p>
        <p>
         For cutaneous lesions concerning for angiosarcoma, multiple punch biopsies of the skin may provide a diagnosis  (
         <a class="graphic graphic_picture graphicRef86926" href="/z/d/graphic/86926.html" rel="external">
          picture 2
         </a>
         ). The available data are insufficient to assess the accuracy of this approach. The specimen should be taken from the darkest and most infiltrated area.
        </p>
        <p class="headingAnchor" id="H4672563">
         <span class="h3">
          Laboratory studies
         </span>
         <span class="headingEndMark">
          —
         </span>
         Serum chemistries and tumor markers are of no value in establishing a diagnosis of breast sarcoma.
        </p>
        <p class="headingAnchor" id="H4672367">
         <span class="h1">
          DIFFERENTIAL DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The differential diagnosis of a primary breast sarcoma includes other primary breast tumors, including inflammatory breast cancer; ductal adenocarcinoma; phyllodes tumor of the breast; breast lymphoma; metastases to the breast from other primary sites; and other benign breast disorders, such as sclerosing adenosis or fibroadenoma. Angiosarcomas with skin discoloration may be mistaken for cellulitis or a breast hematoma. Patients with suspicious findings of discoloration should have a follow-up clinical evaluation within two weeks. If skin findings have not improved or have worsened, then immediate punch biopsy should be performed.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/744.html" rel="external">
          "Clinical features, diagnosis, and staging of newly diagnosed breast cancer"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/768.html" rel="external">
          "Inflammatory breast cancer: Clinical features and treatment"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/128420.html" rel="external">
          "Clinical manifestations and evaluation of locoregional recurrences of breast cancer"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/15779.html" rel="external">
          "Complications of reconstructive and aesthetic breast surgery", section on 'Anaplastic large cell lymphoma'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/96116.html" rel="external">
          "Implant-based breast reconstruction and augmentation", section on 'Concerns over breast implants'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/806.html" rel="external">
          "Overview of benign breast diseases"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/797.html" rel="external">
          "Breast cellulitis and other skin disorders of the breast"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/4711.html" rel="external">
          "Overview of the pathobiology of the non-Hodgkin lymphomas", section on 'Introduction'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H11243257">
         <span class="h1">
          STAGING
         </span>
         <span class="headingEndMark">
          —
         </span>
         Staging of the extent of tumor spread provides a means for formally assigning prognostic categories and is of enormous value in comparing treatment results from individual treatment centers. Treatment decisions are strongly influenced by the stage at initial diagnosis. The most commonly used staging system for breast sarcomas is the same as that used for sarcomas arising at other sites, from the combined American Joint Committee on Cancer (AJCC)/Union for International Cancer Control (UICC)  (
         <a class="graphic graphic_table graphicRef110711" href="/z/d/graphic/110711.html" rel="external">
          table 2
         </a>
         ) [
         <a href="#rid76">
          76
         </a>
         ]. Tumor, node, metastasis (TNM) stage incorporates histologic grade (G), tumor size (T), the presence or absence of lymph node metastases (N), and distant metastases (M) to characterize four stage groupings: I through IV. (See
         <a class="medical medical_review" href="/z/d/html/14259.html" rel="external">
          "Clinical presentation, histopathology, diagnostic evaluation, and staging of soft tissue sarcoma", section on 'Staging'
         </a>
         .)
        </p>
        <p>
         Initial imaging of the primary tumor, to assist in staging, is discussed above. (See
         <a class="local">
          'Imaging'
         </a>
         above.)
        </p>
        <p>
         Nodal status is less informative than it is with epithelial breast cancers. As with soft tissue sarcomas arising at other sites, regional lymph node metastases are uncommon, with the exception of certain histologies, including angiosarcoma. (See
         <a class="medical medical_review" href="/z/d/html/14259.html" rel="external">
          "Clinical presentation, histopathology, diagnostic evaluation, and staging of soft tissue sarcoma", section on 'Regional nodes'
         </a>
         .)
        </p>
        <p>
         All patients should, however, be evaluated for spread of metastatic disease. Computed tomography (CT) of the chest should be obtained for all patients with a primary breast sarcoma, since the lungs are the predominant metastatic site for primary breast sarcoma, similar to the majority of soft tissue sarcomas. Further imaging evaluation for other sites of distant metastases from breast sarcomas is dependent on histology, similar to sarcomas arising from other sites, and is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/14259.html" rel="external">
          "Clinical presentation, histopathology, diagnostic evaluation, and staging of soft tissue sarcoma", section on 'Evaluation for metastatic disease'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4279882335">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/119797.html" rel="external">
          "Society guideline links: Soft tissue sarcoma"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3399099">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Breast sarcomas are primary nonepithelial malignancies arising from the connective tissue within the breast. Sarcomas of the breast can arise de novo (primary) or as a result of treatment for another malignancy (secondary, therapy related), usually with radiation therapy (RT). (See
         <a class="local">
          'Introduction'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A causative factor cannot be identified in many breast sarcomas. Predisposing genetic conditions can sometimes be identified, but these are uncommon. Secondary or treatment-related breast sarcomas most frequently arise following breast cancer treatment, but they can also be associated with RT for other malignancies in which the breast or chest wall is included in the radiated field. Another contributory factor is chronic lymphedema. (See
         <a class="local">
          'Risk factors'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Core biopsy is generally considered the procedure of choice for the definitive diagnosis of a breast sarcoma. Fine needle aspiration is strongly discouraged as it has a low diagnostic accuracy for sarcoma and a false negative result may lead to a delay in diagnosis. For cutaneous lesions, multiple punch biopsies of the skin may provide a diagnosis. (See
         <a class="local">
          'Biopsy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Histologic review by an experienced soft tissue pathologist is critical in making the diagnosis and determining histologic type. In general, angiosarcomas and pleomorphic sarcomas are the most frequently occurring types. (See
         <a class="local">
          'Histologic classification'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Chest computed tomography (CT) should be obtained in all newly diagnosed patients, since the lungs are the predominant metastatic site. Further imaging evaluation for other sites of distant metastases is dependent on histology, similar to sarcomas arising from other sites. (See
         <a class="medical medical_review" href="/z/d/html/14259.html" rel="external">
          "Clinical presentation, histopathology, diagnostic evaluation, and staging of soft tissue sarcoma", section on 'Evaluation for metastatic disease'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1679921604">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges Thomas F DeLaney, MD, who contributed to an earlier version of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Berg JW, Hutter RV. Breast cancer. Cancer 1995; 75:257.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Karlsson P, Holmberg E, Johansson KA, et al. Soft tissue sarcoma after treatment for breast cancer. Radiother Oncol 1996; 38:25.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brady MS, Garfein CF, Petrek JA, Brennan MF. Post-treatment sarcoma in breast cancer patients. Ann Surg Oncol 1994; 1:66.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lagrange JL, Ramaioli A, Chateau MC, et al. Sarcoma after radiation therapy: retrospective multiinstitutional study of 80 histologically confirmed cases. Radiation Therapist and Pathologist Groups of the Fédération Nationale des Centres de Lutte Contre le Cancer. Radiology 2000; 216:197.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Blanchard DK, Reynolds C, Grant CS, et al. Radiation-induced breast sarcoma. Am J Surg 2002; 184:356.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Huang J, Mackillop WJ. Increased risk of soft tissue sarcoma after radiotherapy in women with breast carcinoma. Cancer 2001; 92:172.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McGowan TS, Cummings BJ, O'Sullivan B, et al. An analysis of 78 breast sarcoma patients without distant metastases at presentation. Int J Radiat Oncol Biol Phys 2000; 46:383.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Russell WO, Cohen J, Enzinger F, et al. A clinical and pathological staging system for soft tissue sarcomas. Cancer 1977; 40:1562.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zelek L, Llombart-Cussac A, Terrier P, et al. Prognostic factors in primary breast sarcomas: a series of patients with long-term follow-up. J Clin Oncol 2003; 21:2583.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cozen W, Bernstein L, Wang F, et al. The risk of angiosarcoma following primary breast cancer. Br J Cancer 1999; 81:532.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yap J, Chuba PJ, Thomas R, et al. Sarcoma as a second malignancy after treatment for breast cancer. Int J Radiat Oncol Biol Phys 2002; 52:1231.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Terrier P, Terrier-Lacombe MJ, Mouriesse H, et al. Primary breast sarcoma: a review of 33 cases with immunohistochemistry and prognostic factors. Breast Cancer Res Treat 1989; 13:39.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Adem C, Reynolds C, Ingle JN, Nascimento AG. Primary breast sarcoma: clinicopathologic series from the Mayo Clinic and review of the literature. Br J Cancer 2004; 91:237.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Blanchard DK, Reynolds CA, Grant CS, Donohue JH. Primary nonphylloides breast sarcomas. Am J Surg 2003; 186:359.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pandey M, Mathew A, Abraham EK, Rajan B. Primary sarcoma of the breast. J Surg Oncol 2004; 87:121.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Granier G, Lemoine MC, Mares P, et al. [Primary angiosarcoma of the male breast]. Ann Pathol 2005; 25:235.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Al-Benna S, Poggemann K, Steinau HU, Steinstraesser L. Diagnosis and management of primary breast sarcoma. Breast Cancer Res Treat 2010; 122:619.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           May DS, Stroup NE. The incidence of sarcomas of the breast among women in the United States, 1973-1986. Plast Reconstr Surg 1991; 87:193.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marchal C, Weber B, de Lafontan B, et al. Nine breast angiosarcomas after conservative treatment for breast carcinoma: a survey from French comprehensive Cancer Centers. Int J Radiat Oncol Biol Phys 1999; 44:113.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vorburger SA, Xing Y, Hunt KK, et al. Angiosarcoma of the breast. Cancer 2005; 104:2682.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shet T, Malaviya A, Nadkarni M, et al. Primary angiosarcoma of the breast: observations in Asian Indian women. J Surg Oncol 2006; 94:368.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sher T, Hennessy BT, Valero V, et al. Primary angiosarcomas of the breast. Cancer 2007; 110:173.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moore MP, Kinne DW. Breast sarcoma. Surg Clin North Am 1996; 76:383.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           STEWART FW, TREVES N. Lymphangiosarcoma in postmastectomy lymphedema; a report of six cases in elephantiasis chirurgica. Cancer 1948; 1:64.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sheth GR, Cranmer LD, Smith BD, et al. Radiation-induced sarcoma of the breast: a systematic review. Oncologist 2012; 17:405.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Penel N, Grosjean J, Robin YM, et al. Frequency of certain established risk factors in soft tissue sarcomas in adults: a prospective descriptive study of 658 cases. Sarcoma 2008; 2008:459386.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kuttesch JF Jr, Wexler LH, Marcus RB, et al. Second malignancies after Ewing's sarcoma: radiation dose-dependency of secondary sarcomas. J Clin Oncol 1996; 14:2818.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Overgaard M, Hansen PS, Overgaard J, et al. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial. N Engl J Med 1997; 337:949.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ragaz J, Jackson SM, Le N, et al. Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer. N Engl J Med 1997; 337:956.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Overgaard M, Jensen MB, Overgaard J, et al. Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial. Lancet 1999; 353:1641.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rubino C, Shamsaldin A, Lê MG, et al. Radiation dose and risk of soft tissue and bone sarcoma after breast cancer treatment. Breast Cancer Res Treat 2005; 89:277.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           O'Brien MM, Donaldson SS, Balise RR, et al. Second malignant neoplasms in survivors of pediatric Hodgkin's lymphoma treated with low-dose radiation and chemotherapy. J Clin Oncol 2010; 28:1232.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kirova YM, Vilcoq JR, Asselain B, et al. Radiation-induced sarcomas after radiotherapy for breast carcinoma: a large-scale single-institution review. Cancer 2005; 104:856.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Taghian A, de Vathaire F, Terrier P, et al. Long-term risk of sarcoma following radiation treatment for breast cancer. Int J Radiat Oncol Biol Phys 1991; 21:361.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zucali R, Merson M, Placucci M, et al. Soft tissue sarcoma of the breast after conservative surgery and irradiation for early mammary cancer. Radiother Oncol 1994; 30:271.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pierce SM, Recht A, Lingos TI, et al. Long-term radiation complications following conservative surgery (CS) and radiation therapy (RT) in patients with early stage breast cancer. Int J Radiat Oncol Biol Phys 1992; 23:915.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mery CM, George S, Bertagnolli MM, Raut CP. Secondary sarcomas after radiotherapy for breast cancer: sustained risk and poor survival. Cancer 2009; 115:4055.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Laskin WB, Silverman TA, Enzinger FM. Postradiation soft tissue sarcomas. An analysis of 53 cases. Cancer 1988; 62:2330.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Davidson T, Westbury G, Harmer CL. Radiation-induced soft-tissue sarcoma. Br J Surg 1986; 73:308.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chahin F, Paramesh A, Dwivedi A, et al. Angiosarcoma of the breast following breast preservation therapy and local radiation therapy for breast cancer. Breast J 2001; 7:120.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mito JK, Mitra D, Barysauskas CM, et al. A Comparison of Outcomes and Prognostic Features for Radiation-Associated Angiosarcoma of the Breast and Other Radiation-Associated Sarcomas. Int J Radiat Oncol Biol Phys 2019; 104:425.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Strobbe LJ, Peterse HL, van Tinteren H, et al. Angiosarcoma of the breast after conservation therapy for invasive cancer, the incidence and outcome. An unforseen sequela. Breast Cancer Res Treat 1998; 47:101.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Billings SD, McKenney JK, Folpe AL, et al. Cutaneous angiosarcoma following breast-conserving surgery and radiation: an analysis of 27 cases. Am J Surg Pathol 2004; 28:781.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sessions SC, Smink RD Jr. Cutaneous angiosarcoma of the breast after segmental mastectomy and radiation therapy. Arch Surg 1992; 127:1362.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fineberg S, Rosen PP. Cutaneous angiosarcoma and atypical vascular lesions of the skin and breast after radiation therapy for breast carcinoma. Am J Clin Pathol 1994; 102:757.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Krueger EA, Fraass BA, McShan DL, et al. Potential gains for irradiation of chest wall and regional nodes with intensity modulated radiotherapy. Int J Radiat Oncol Biol Phys 2003; 56:1023.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Woodward AH, Ivins JC, Soule EH. Lymphangiosarcoma arising in chronic lymphedematous extremities. Cancer 1972; 30:562.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zahm SH, Fraumeni JF Jr. The epidemiology of soft tissue sarcoma. Semin Oncol 1997; 24:504.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McGregor GI, Knowling MA, Este FA. Sarcoma and Cystosarcoma phyllodes tumors of the breast--a retrospective review of 58 cases. Am J Surg 1994; 167:477.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee JS, Yoon K, Onyshchenko M. Sarcoma of the Breast: Clinical Characteristics and Outcomes of 991 Patients from the National Cancer Database. Sarcoma 2021; 2021:8828158.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Confavreux C, Lurkin A, Mitton N, et al. Sarcomas and malignant phyllodes tumours of the breast--a retrospective study. Eur J Cancer 2006; 42:2715.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bousquet G, Confavreux C, Magné N, et al. Outcome and prognostic factors in breast sarcoma: a multicenter study from the rare cancer network. Radiother Oncol 2007; 85:355.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rosen PP, Kimmel M, Ernsberger D. Mammary angiosarcoma. The prognostic significance of tumor differentiation. Cancer 1988; 62:2145.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Donnell RM, Rosen PP, Lieberman PH, et al. Angiosarcoma and other vascular tumors of the breast. Am J Surg Pathol 1981; 5:629.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Luini A, Gatti G, Diaz J, et al. Angiosarcoma of the breast: the experience of the European Institute of Oncology and a review of the literature. Breast Cancer Res Treat 2007; 105:81.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nascimento AF, Raut CP, Fletcher CD. Primary angiosarcoma of the breast: clinicopathologic analysis of 49 cases, suggesting that grade is not prognostic. Am J Surg Pathol 2008; 32:1896.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Deyrup AT, Weiss SW. Grading of soft tissue sarcomas: the challenge of providing precise information in an imprecise world. Histopathology 2006; 48:42.
          </a>
         </li>
         <li class="breakAll">
          Soft tissue and bone tumours. In: WHO Classification of Tumours, 5th ed, WHO Classification of Tumours Editorial Board (Ed), IARC Press, 2020.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gutman H, Pollock RE, Ross MI, et al. Sarcoma of the breast: implications for extent of therapy. The M. D. Anderson experience. Surgery 1994; 116:505.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pollard SG, Marks PV, Temple LN, Thompson HH. Breast sarcoma. A clinicopathologic review of 25 cases. Cancer 1990; 66:941.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           North JH Jr, McPhee M, Arredondo M, Edge SB. Sarcoma of the breast: implications of the extent of local therapy. Am Surg 1998; 64:1059.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shabahang M, Franceschi D, Sundaram M, et al. Surgical management of primary breast sarcoma. Am Surg 2002; 68:673.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Morgan EA, Kozono DE, Wang Q, et al. Cutaneous radiation-associated angiosarcoma of the breast: poor prognosis in a rare secondary malignancy. Ann Surg Oncol 2012; 19:3801.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smith TB, Gilcrease MZ, Santiago L, et al. Imaging features of primary breast sarcoma. AJR Am J Roentgenol 2012; 198:W386.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yang WT, Muttarak M, Ho LW. Nonmammary malignancies of the breast: ultrasound, CT, and MRI. Semin Ultrasound CT MR 2000; 21:375.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schnarkowski P, Kessler M, Arnholdt H, Helmberger T. Angiosarcoma of the breast: mammographic, sonographic, and pathological findings. Eur J Radiol 1997; 24:54.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liberman L, Dershaw DD, Kaufman RJ, Rosen PP. Angiosarcoma of the breast. Radiology 1992; 183:649.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Williams EV, Banerjee D, Dallimore N, Monypenny IJ. Angiosarcoma of the breast following radiation therapy. Eur J Surg Oncol 1999; 25:221.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fant J, Grant M, May S, et al. Angiosarcoma of the breast: mammographic, clinical, and pathologic correlation. Breast J 2003; 9:252.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hodgson NC, Bowen-Wells C, Moffat F, et al. Angiosarcomas of the breast: a review of 70 cases. Am J Clin Oncol 2007; 30:570.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mills TD, Vinnicombe SJ, Wells CA, Carpenter R. Angiosarcoma of the breast after wide local excision and radiotherapy for breast carcinoma. Clin Radiol 2002; 57:63.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sanders LM, Groves AC, Schaefer S. Cutaneous angiosarcoma of the breast on MRI. AJR Am J Roentgenol 2006; 187:W143.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yang WT, Hennessy BT, Dryden MJ, et al. Mammary angiosarcomas: imaging findings in 24 patients. Radiology 2007; 242:725.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Glazebrook KN, Morton MJ, Reynolds C. Vascular tumors of the breast: mammographic, sonographic, and MRI appearances. AJR Am J Roentgenol 2005; 184:331.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marchant LK, Orel SG, Perez-Jaffe LA, et al. Bilateral angiosarcoma of the breast on MR imaging. AJR Am J Roentgenol 1997; 169:1009.
          </a>
         </li>
         <li class="breakAll">
          AJCC Cancer Staging Manual, 7th ed, Edge SB, Byrd DR, Compton CC, et al (Eds), Springer, New York 2010. p.291.
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 811 Version 45.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8001000" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Breast cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8850423" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Soft tissue sarcoma after treatment for breast cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7834431" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Post-treatment sarcoma in breast cancer patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10887248" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Sarcoma after radiation therapy: retrospective multiinstitutional study of 80 histologically confirmed cases. Radiation Therapist and Pathologist Groups of the Fédération Nationale des Centres de Lutte Contre le Cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12383902" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Radiation-induced breast sarcoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11443624" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Increased risk of soft tissue sarcoma after radiotherapy in women with breast carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10661345" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : An analysis of 78 breast sarcoma patients without distant metastases at presentation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/907970" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : A clinical and pathological staging system for soft tissue sarcomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12829679" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Prognostic factors in primary breast sarcomas: a series of patients with long-term follow-up.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10507781" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : The risk of angiosarcoma following primary breast cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11955733" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Sarcoma as a second malignancy after treatment for breast cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2468372" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Primary breast sarcoma: a review of 33 cases with immunohistochemistry and prognostic factors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15187996" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Primary breast sarcoma: clinicopathologic series from the Mayo Clinic and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14553850" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Primary nonphylloides breast sarcomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15334638" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Primary sarcoma of the breast.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16230950" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : [Primary angiosarcoma of the male breast].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20480227" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Diagnosis and management of primary breast sarcoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1984266" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : The incidence of sarcomas of the breast among women in the United States, 1973-1986.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10219803" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Nine breast angiosarcomas after conservative treatment for breast carcinoma: a survey from French comprehensive Cancer Centers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16288486" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Angiosarcoma of the breast.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16967461" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Primary angiosarcoma of the breast: observations in Asian Indian women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17541936" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Primary angiosarcomas of the breast.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8610270" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Breast sarcoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18867440" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Lymphangiosarcoma in postmastectomy lymphedema; a report of six cases in elephantiasis chirurgica.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22334455" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Radiation-induced sarcoma of the breast: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18497869" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Frequency of certain established risk factors in soft tissue sarcomas in adults: a prospective descriptive study of 658 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8874344" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Second malignancies after Ewing's sarcoma: radiation dose-dependency of secondary sarcomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9395428" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9309100" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10335782" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15754127" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Radiation dose and risk of soft tissue and bone sarcoma after breast cancer treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20124178" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Second malignant neoplasms in survivors of pediatric Hodgkin's lymphoma treated with low-dose radiation and chemotherapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15981282" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Radiation-induced sarcomas after radiotherapy for breast carcinoma: a large-scale single-institution review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1648044" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Long-term risk of sarcoma following radiation treatment for breast cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8209012" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Soft tissue sarcoma of the breast after conservative surgery and irradiation for early mammary cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1639653" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Long-term radiation complications following conservative surgery (CS) and radiation therapy (RT) in patients with early stage breast cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19526590" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Secondary sarcomas after radiotherapy for breast cancer: sustained risk and poor survival.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3179948" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Postradiation soft tissue sarcomas. An analysis of 53 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3697664" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Radiation-induced soft-tissue sarcoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11328320" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Angiosarcoma of the breast following breast preservation therapy and local radiation therapy for breast cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30703514" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : A Comparison of Outcomes and Prognostic Features for Radiation-Associated Angiosarcoma of the Breast and Other Radiation-Associated Sarcomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9497098" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Angiosarcoma of the breast after conservation therapy for invasive cancer, the incidence and outcome. An unforseen sequela.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15166670" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Cutaneous angiosarcoma following breast-conserving surgery and radiation: an analysis of 27 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1332648" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Cutaneous angiosarcoma of the breast after segmental mastectomy and radiation therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7801888" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Cutaneous angiosarcoma and atypical vascular lesions of the skin and breast after radiation therapy for breast carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12829138" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Potential gains for irradiation of chest wall and regional nodes with intensity modulated radiotherapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5051679" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Lymphangiosarcoma arising in chronic lymphedematous extremities.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9344316" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : The epidemiology of soft tissue sarcoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8185030" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Sarcoma and Cystosarcoma phyllodes tumors of the breast--a retrospective review of 58 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33542674" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Sarcoma of the Breast: Clinical Characteristics and Outcomes of 991 Patients from the National Cancer Database.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17023158" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Sarcomas and malignant phyllodes tumours of the breast--a retrospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18023492" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Outcome and prognostic factors in breast sarcoma: a multicenter study from the rare cancer network.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3179927" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Mammary angiosarcoma. The prognostic significance of tumor differentiation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7199829" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Angiosarcoma and other vascular tumors of the breast.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17115110" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Angiosarcoma of the breast: the experience of the European Institute of Oncology and a review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18813119" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Primary angiosarcoma of the breast: clinicopathologic analysis of 49 cases, suggesting that grade is not prognostic.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16359536" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Grading of soft tissue sarcomas: the challenge of providing precise information in an imprecise world.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16359536" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Grading of soft tissue sarcomas: the challenge of providing precise information in an imprecise world.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8079181" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Sarcoma of the breast: implications for extent of therapy. The M. D. Anderson experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2386920" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Breast sarcoma. A clinicopathologic review of 25 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9798768" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Sarcoma of the breast: implications of the extent of local therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12206600" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Surgical management of primary breast sarcoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22890593" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Cutaneous radiation-associated angiosarcoma of the breast: poor prognosis in a rare secondary malignancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22451578" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Imaging features of primary breast sarcoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11071618" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Nonmammary malignancies of the breast: ultrasound, CT, and MRI.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9056150" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Angiosarcoma of the breast: mammographic, sonographic, and pathological findings.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1584913" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Angiosarcoma of the breast.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10218470" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Angiosarcoma of the breast following radiation therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12752640" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Angiosarcoma of the breast: mammographic, clinical, and pathologic correlation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18091049" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Angiosarcomas of the breast: a review of 70 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11798205" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Angiosarcoma of the breast after wide local excision and radiotherapy for breast carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16861502" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Cutaneous angiosarcoma of the breast on MRI.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17325063" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Mammary angiosarcomas: imaging findings in 24 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15615997" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Vascular tumors of the breast: mammographic, sonographic, and MRI appearances.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9308452" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Bilateral angiosarcoma of the breast on MR imaging.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
